Osmanovic, Alma
Widjaja, Maylin
Förster, Alisa
Weder, Julia
Wattjes, Mike P.
Lange, Inken
Sarikidi, Anastasia
Auber, Bernd
Raab, Peter
Christians, Anne
Preller, Matthias
Petri, Susanne
Weber, Ruthild G.
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung (KlinStrucMed program of Hannover Medical School)
Petermax Müller-Stiftung
Hochschulinterne Leistungsförderung (HiLF) program of Hannover Medical School
Deutsche Forschungsgemeinschaft (PRACTIS - Clinician Scientist Program of Hannover Medical School, grant no. ME3696/3-1, KO5614/2-1)
German Neuromuscular Society
Federal Ministry of Education and Research
German Israeli Foundation for Scientific Research and Development
EU Joint Programme for Neurodegenerative Disease Research
Article History
Received: 5 March 2020
Revised: 20 April 2020
Accepted: 22 April 2020
First Online: 23 May 2020
Compliance with ethical standards
:
: AO received honoraria from Biogen; MPW received honoraria from Bayer, Biogen, Biologix, Celgene, Genilac, Imcyse, IXICO, Medison, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Spinger Healthcare, and Teva; PR received honoraria from Biogen and IXICO; SP received honoraria from Biogen, Cytokinetics, Inc., Desitin Pharma, Novartis, Roche, and Teva. MW, AF, JW, IL, AS, BA, AC, MP, and RGW report no conflict of interest.
: This study was approved by the local ethics review board of Hannover Medical School and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: All patients gave their written informed consent before entering the study.